TY - JOUR
T1 - POU3F3-related disorder
T2 - Defining the phenotype and expanding the molecular spectrum
AU - Rossi, Alessandra
AU - Blok, Lot Snijders
AU - Neuser, Sonja
AU - Klöckner, Chiara
AU - Platzer, Konrad
AU - Faivre, Laurence Olivier
AU - Weigand, Heike
AU - Dentici, Maria L
AU - Tartaglia, Marco
AU - Niceta, Marcello
AU - Alfieri, Paolo
AU - Srivastava, Siddharth
AU - Coulter, David
AU - Smith, Lacey
AU - Vinorum, Kristin
AU - Cappuccio, Gerarda
AU - Brunetti-Pierri, Nicola
AU - Torun, Deniz
AU - Arslan, Mutluay
AU - Lauridsen, Mathilde F
AU - Murch, Oliver
AU - Irving, Rachel
AU - Lynch, Sally A
AU - Mehta, Sarju G
AU - Carmichael, Jenny
AU - Zonneveld-Huijssoon, Evelien
AU - de Vries, Bert
AU - Kleefstra, Tjitske
AU - Johannesen, Katrine M
AU - Westphall, Ian T
AU - Hughes, Susan S
AU - Smithson, Sarah
AU - Evans, Julie
AU - Dudding-Byth, Tracy
AU - Simon, Marleen
AU - van Binsbergen, Ellen
AU - Herkert, Johanna C
AU - Beunders, Gea
AU - Oppermann, Henry
AU - Bakal, Mert
AU - Møller, Rikke S
AU - Rubboli, Guido
AU - Bayat, Allan
N1 - Funding Information:
The authors would like to thank the families for their participation. This study makes use of data generated by the DECIPHER community. A full list of centers who contributed to the generation of the data is available from https://deciphergenomics.org/about/stats and via email from [email protected] . Funding for the DECIPHER project was provided by Wellcome. This study was also, in part, generated within the European Reference Network ITHACA (NBP). This work was in part supported by the Telethon Foundation, Telethon Undiagnosed Diseases Program (TUDP, GSP15001 to Nicola Brunetti‐Pierri). Siddharth Srivastava is funded by NIH‐NINDS (K23NS119666). Allan Bayat is funded by a BRIDGE—Translational Excellence Program grant funded by the Novo Nordisk Foundation, grant agreement number: NNF20SA0064340.
Funding Information:
The authors would like to thank the families for their participation. This study makes use of data generated by the DECIPHER community. A full list of centers who contributed to the generation of the data is available from https://deciphergenomics.org/about/stats and via email from [email protected]. Funding for the DECIPHER project was provided by Wellcome. This study was also, in part, generated within the European Reference Network ITHACA (NBP). This work was in part supported by the Telethon Foundation, Telethon Undiagnosed Diseases Program (TUDP, GSP15001 to Nicola Brunetti-Pierri). Siddharth Srivastava is funded by NIH-NINDS (K23NS119666). Allan Bayat is funded by a BRIDGE—Translational Excellence Program grant funded by the Novo Nordisk Foundation, grant agreement number: NNF20SA0064340.
Publisher Copyright:
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2023/8
Y1 - 2023/8
N2 - POU3F3 variants cause developmental delay, behavioral problems, hypotonia and dysmorphic features. We investigated the phenotypic and genetic landscape, and genotype-phenotype correlations in individuals with POU3F3-related disorders. We recruited unpublished individuals with POU3F3 variants through international collaborations and obtained updated clinical data on previously published individuals. Trio exome sequencing or single exome sequencing followed by segregation analysis were performed in the novel cohort. Functional effects of missense variants were investigated with 3D protein modeling. We included 28 individuals (5 previously published) from 26 families carrying POU3F3 variants; 23 de novo and one inherited from an affected parent. Median age at study inclusion was 7.4 years. All had developmental delay mainly affecting speech, behavioral difficulties, psychiatric comorbidities and dysmorphisms. Additional features included gastrointestinal comorbidities, hearing loss, ophthalmological anomalies, epilepsy, sleep disturbances and joint hypermobility. Autism, hearing and eye comorbidities, dysmorphisms were more common in individuals with truncating variants, whereas epilepsy was only associated with missense variants. In silico structural modeling predicted that all (likely) pathogenic variants destabilize the DNA-binding region of POU3F3. Our study refined the phenotypic and genetic landscape of POU3F3-related disorders, it reports the functional properties of the identified pathogenic variants, and delineates some genotype-phenotype correlations.
AB - POU3F3 variants cause developmental delay, behavioral problems, hypotonia and dysmorphic features. We investigated the phenotypic and genetic landscape, and genotype-phenotype correlations in individuals with POU3F3-related disorders. We recruited unpublished individuals with POU3F3 variants through international collaborations and obtained updated clinical data on previously published individuals. Trio exome sequencing or single exome sequencing followed by segregation analysis were performed in the novel cohort. Functional effects of missense variants were investigated with 3D protein modeling. We included 28 individuals (5 previously published) from 26 families carrying POU3F3 variants; 23 de novo and one inherited from an affected parent. Median age at study inclusion was 7.4 years. All had developmental delay mainly affecting speech, behavioral difficulties, psychiatric comorbidities and dysmorphisms. Additional features included gastrointestinal comorbidities, hearing loss, ophthalmological anomalies, epilepsy, sleep disturbances and joint hypermobility. Autism, hearing and eye comorbidities, dysmorphisms were more common in individuals with truncating variants, whereas epilepsy was only associated with missense variants. In silico structural modeling predicted that all (likely) pathogenic variants destabilize the DNA-binding region of POU3F3. Our study refined the phenotypic and genetic landscape of POU3F3-related disorders, it reports the functional properties of the identified pathogenic variants, and delineates some genotype-phenotype correlations.
KW - autism
KW - cupped ears
KW - epilepsy
KW - neurodevelopmental disorder
KW - POU3F3
UR - http://www.scopus.com/inward/record.url?scp=85159066767&partnerID=8YFLogxK
U2 - 10.1111/cge.14353
DO - 10.1111/cge.14353
M3 - Article
C2 - 37165752
SN - 0009-9163
VL - 104
SP - 186
EP - 197
JO - Clinical Genetics
JF - Clinical Genetics
IS - 2
ER -